|
Match
|
Document |
Document Title |
|
|
5603936 |
Process for removing light absorbing compounds from epidermal plant cells
A process is provided for harvesting light absorbing compounds from the epidermal cells of a plant. The plant is subjected to artificial light having wavelengths in the range of 260 to 400 nm. The...
|
|
|
5597564 |
Method of administering a microgranular preparation to the intestinal region of animals
A microgranular preparation having a core of biologically active material that is encapsulated by a water soluble film that is covered by an enteric coating of either an alkali soluble, acid...
|
|
|
5595743 |
Preparation of herbal medicines by using a multi-enzyme system, herbal medicines prepared and their uses
This invention relates to a process for preparing a herbal medicine by using a multi-enzyme to hydrolyze raw materials. The multi-enzyme system comprises cellulases, proteases, amylases, lipases...
|
|
|
5593837 |
Clinical disorders associated with carboxypeptidase E mutation
Disclosed herein is a therapeutic method for treating a clinical disorder associated with a mutation in the carboxypeptidase E gene. In the therapeutic method of the invention, a molecule having...
|
|
|
5593674 |
Plasma carboxypeptidase
A novel polypeptide, designated plasma carboxypeptidase B (PCPB), has been purified from human plasma. It has been cloned from a human liver cDNA library using PCR amplification. Provided herein is...
|
|
|
5589169 |
Method and therapeutic compositions for the prevention of fibrin deposition or adhesions
A method and pharmaceutical composition for the prevention of fibrin deposition or adhesion formation by topical application of a composition to a site of potential fibrin deposition or adhesion...
|
|
|
5580962 |
Parenterally administrable drug having thrombolytic activity and containing protein C
A thrombolytic, parenterally administrable drug containing activated protein C is provided for. The drug is free of serum amyloid P, thrombin activity, infectious agents and antibodies against...
|
|
|
5580559 |
Hybrid plasminogen activator
Novel single-chain hybrid plasminogen activators having an amino acid sequence composed of at least two subsequences corresponding in amino acid identity and number to subsequences of human t-PA...
|
|
|
5578305 |
Methods and preparations for preventing adhesions to organs and parts of organs
Pharmaceutical composition for prevention of adhesions to body organs or parts of body organs within a body cavity at a site of inflammation is disclosed. The pharmaceutical composition contains...
|
|
|
5571708 |
Thrombin-activatable plasminogen activator
A new chimeric plasminogen activator with high fibrin affinity was designed to bind to a fibrin clot and initiate clot destruction in the presence of thrombin, but not plasmin. The chimeric...
|
|
|
5560910 |
Topical anti-inflammatory composition and method
The present invention comprises compositions and methods that are useful for topically treating inflammation caused by a wide variety of diseases. The compositions comprise an effective amount of a...
|
|
|
5556621 |
Tissue plasminogen activator and method of use
The present invention relates to improved plasminogen activators (improved t-PA) which have a prolonged biological half life, an increased stability to heat and acids and can be expected to be...
|
|
|
5549893 |
Use of protein C in the treatment of purpura fulminans
There is disclosed the use of protein C or activated protein C for preparing a drug useful for the maintenance and improvement of the microcirculation in patients suffering from circulatory...
|
|
|
5549894 |
Disinfecton formulations and methods using D-enantiomeric anti-microbial peptides
A method for disinfecting a contact lens, includes the step of contacting the lens with an effective amount of at least one D-enantiomeric anti-microbial agent for a period of time sufficient to...
|
|
|
5545402 |
Skin care method and composition
A composition for topical application to the skin for alleviation or prevention of dry flaky skin condition, dandruff or acne comprising one or more stratum corneum thiol proteases. The composition...
|
|
|
5520913 |
Tissue plasminogen activator having zymogenic properties
Tissue plasminogen activator (t-PA) zymogens and variants are prepared, including a fibrinolytically active variant of t-PA that has an amino acid alteration at a site within the protease domain of...
|
|
|
5520911 |
Variants of plasminogen activators and processes for their production
A fibrinolytically active amino acid sequence variant of a plasminogen activator is prepared that has one or more glycosylation sites in regions that are not glycosylated in the native molecule....
|
|
|
5510330 |
Combinations of thrombolytically active proteins and non-heparin anticoagulants, and uses thereof.
The invention involves thromboembolically effective compositions and therapeutic methods. Thrombolytically active proteins are combined with anticoagulants, as long as the anticoagulant is not...
|
|
|
5505943 |
Compositions containing protease produced by vibrio and method of use in debridement and wound healing
Compositions and methods of use are provided for debriding and wound healing applications. The compositions contain certain proteases produced by microorganisms of the genus Vibrio
|
|
|
5503850 |
Method and composition for the treatment of thrombosis in a mammal
A composition comprising a plurality of microcapsules suitable for parenteral injection into a mammal comprising a plasminogen activator-containing core, and a semi-permeable biocompatible layer...
|
|
|
5496549 |
Bispecific monoclonal antibodies, thrombolytic agent and method of cell lysis
Disclosed are a bispecific hybrid MoAb having specificity for both an activated platelet and a substance having thrombolytic activity, and a thrombolytic agent comprising the above bispecific MoAb...
|
|
|
5491082 |
Plasminogen activator covalently bonded to a porous body of β-tricalcium phosphate
A plasminogen activator such as urokinase or tissue plasminogen activator is covalently bonded to a porous body composed of calcium phosphate to form a plasminogen activator-porous body complex....
|
|
|
5478558 |
Method of dissolving venous Thrombi using drug containing activated Protein C
A method of dissolving venous thrombi using a thrombolytic, parenterally administrable drug containing activated protein C is described. The drug can be free of serum amyloid P, thrombin activity,...
|
|
|
5472692 |
Pro-urokinase mutants
The invention relates to thrombolytically active pro-urokinase (pro-UK) mutants comprising the amino acid sequence of native pro-UK, but including a mutation which causes the pro-UK mutants to...
|
|
|
5470849 |
γ-turn peptidomimetics as fibrinogen antagonists
This invention relates to a method of inhibiting platelet aggregation, and compounds which are mimics of the peptide sequence Arg-Gly-Asp.
|
|
|
5466547 |
Enteric coated papain-containing food supplement for controlling auto immune diseases
Food supplement containing enteric coated papain for controlling auto immune diseases, more particularly AIDS and the symptoms of disease related thereto. Vitamin E is added as an antioxidant to...
|
|
|
5456909 |
Glycoform fractions of recombinant soluble complement receptor 1 (sCR1) having extended half-lives in vivo
The present invention relates to novel glycoforms and preparations of the soluble complement receptor type 1 (sCR1), and their uses in the therapy of complement mediated diseases and disorders...
|
|
|
5443981 |
Acremonium typhinum ATCC 74228 which exhibits endoproteolytic activity
A crude membrane fraction of leaf sheath tissue of a grass endophytically infected by A. typhinum is produced. The extract exhibits endoproteolytic activity in the presence of detergent or after...
|
|
|
5439679 |
Peptide plasminogen activators
Novel polypeptide compositions based on the amino acid sequence of tissue plasminogen activator (tPA) are provided having improved properties over natural tissue plasminogen activator....
|
|
|
5436137 |
DNA sequence which encodes a peptide capable of promoting acrosome reaction
A pure DNA encoding a peptide which is capable of promoting acrosome reaction and the encoded peptide. Also disclosed are a vector and a cell containing such a DNA, a pharmaceutical composition...
|
|
|
5425942 |
Polyfunctinal protease
The present invention provides a human polyfuctional protease chracterized in that the protease has unique enzymological and physicochemical properties:
|
|
|
5422260 |
Human factor VIII:c muteins
This invention relates to recombinant Factor VIII:c variants, methods to produce the variants and pharmaceutical compositions containing same.
|
|
|
5409700 |
Pharmaceutical compositions comprising modified and unmodified plasminogen activators
The present invention relates to pharmaceutical compositions comprising a combination of two different plasminogen activators which are used for the prophylaxis and therapie of thrombosis.
|
|
|
5395613 |
Process for degradation of keratin, keratinaceous material, collagen and collagenaceous material with enzyme material, cell-free culture or cell culture from micrococcus sedentarius
A process for the degradation of keratin, keratinaceous material, collagen or collagenaceous material comprising contacting keratin, keratinaceous material, collagen or collagenaceous material with...
|
|
|
5391371 |
Use of an enzyme containing granulate in a method for production of a pelletized fodder
An enzyme containing T-granulate, coated with a coating agent comprising a high melting fat or wax, is combined with a mixture containing fodder components, and the combination is steam treated and...
|
|
|
5385732 |
Variants of tissue plasminogen activator, compositions and methods of use for same
A fibrinolytically active amino acid sequence variant of a plasminogen activator is prepared that has one or more glycosylation sites in regions that are not glycosylated in the native molecule....
|
|
|
5372812 |
Composition and method for acceleration of clot lysis
The present invention relates to a novel treatment for blood clots within a patient or myocardial infarction which comprises administering a hapten-binding molecule capable of preventing inhibition...
|
|
|
5364622 |
Methods for preventing adhesions to organs and parts of organs by application of tissue plasminogen activator and hydroxyethylcellulose hydrogel
A method for the prevention of adhesions to body organs and parts of organs caused by therapeutic intervention by applying a pharmaceutical composition of tissue plasminogen activator and an...
|
|
|
5356625 |
Microgranular preparation useful in the delivery of biologically active materials to the intestinal regions of animals
A microgranular preparation having a core of biologically active material that is encapsulated by a water soluble film that is covered by an enteric coating of either an alkali soluble, acid...
|
|
|
5350578 |
Inhibition of arterial thrombotic occlusion or thromboembolism
The method of preventing arterial thrombotic occlusion or thromboembolism by administering plasma-derived or recombinant produced protein C alone or in combination with a thrombolytic agent or...
|
|
|
5338546 |
Tissue plasminogen activator variants with decreased clearance
Biologically active tissue plasminogen activator (t-PA) variants with decreased clearance as compared to wild-type t-PA are prepared, including variants that have one or more amino acid alterations...
|
|
|
5334384 |
Process for purification of streptakinase using a reducing agent
A process for the separation of streptokinase from contaminating proteins in a streptokinase-containing mixture, which comprises treating the mixture with a reducing agent to reduce disulphide...
|
|
|
5326562 |
Pharmaceutical dosage unit for treating inflammation comprising protease nexin-I
Methods and pharmaceutical compositions for treatment of inflammation and arthritis using protease nexin-I as an active ingredient are disclosed.
|
|
|
5324514 |
Compositions of digestive enzymes and salts of bile acids and process for preparation thereof
Disclosed are gastric acid-resistant polymer-coated digestive enzymes/ursodeoxycholate compositions, process for their preparations and methods of treating digestive disorders, treating impaired...
|
|
|
5316766 |
Thrombosis treatment with fibrinolytics and prostacyclins
The combination of a fibrinolytic and a prostacyclin analogue is very useful for thrombosis treatment, especially to avoid subsequent rethrombosis.
|
|
|
5315998 |
Booster for therapy of diseases with ultrasound and pharmaceutical liquid composition containing the same
A booster comprising a plenty of microbubbles of a gas in a liquid, e.g. about 4×10 7 cells/ml of microbubbles of a gas having a diameter of 0.1 to 100 μm in a 3 to 5% human serum albumin...
|
|
|
5314692 |
Enzyme premix for feed and method
A thermostable premix for use in animal feeds which comprises a carrier material onto which an enzyme solution containing enzymes which are not inherently heat stable are absorbed.
|
|
|
5302390 |
Hybrid proteins of human plasminogen and human t-PA, pharmaceutical compositions and methods of treatment
A hybrid plasminogen activator which comprises the five kringle domains of plasminogen linked to the B-chain of t-PA or u-PA via an amino acid sequence comprising, respectively, the t-PA cleavage...
|
|
|
5296357 |
Method for the detection of plasminogen activators, their inhibitors of stimulators
The invention relates to a method for the detection of the functional activity of plasminogen activators and of their inhibitors and stimulators in biological samples, and to reagents for this method.
|
|
|
5290692 |
Bioadaptable porous crystalline glass containing an immobilized fibrinolytic enzyme for dissolving blood clots
A fibrinolytic enzyme such as urokinase, tissue plasminogen activator or streptokinase is covalently bounded to a bioadaptable porous crystalline glass to produce a thrombolytic material....
|